- 37-7700 - Invitrogen Antibodies UBQLN2 antibody

Submitted references Human Ubiquilin 2 and TDP-43 copathology drives neurodegeneration in transgenic Caenorhabditis elegans.

Saxton AD, Kraemer BC
G3 (Bethesda, Md.) 2021 Aug 7;11(8)

Overexpression of UBQLN1 reduces neuropathology in the P497S UBQLN2 mouse model of ALS/FTD.

Wang S, Tatman M, Monteiro MJ
Acta neuropathologica communications 2020 Oct 7;8(1):164

Signature changes in ubiquilin expression in the R6/2 mouse model of Huntington's disease.

Safren N, Chang L, Dziki KM, Monteiro MJ
Brain research 2015 Feb 9;1597:37-46

Ubiquilin-1 overexpression increases the lifespan and delays accumulation of Huntingtin aggregates in the R6/2 mouse model of Huntington's disease.

Safren N, El Ayadi A, Chang L, Terrillion CE, Gould TD, Boehning DF, Monteiro MJ
PloS one 2014;9(1):e87513

Nuclear proteasomes carry a constitutive posttranslational modification which derails SDS-PAGE (but not CTAB-PAGE).

Pitcher DS, de Mattos-Shipley K, Wang Z, Tzortzis K, Goudevenou K, Flynn H, Bohn G, Rahemtulla A, Roberts I, Snijders AP, Karadimitris A, Kleijnen MF
Biochimica et biophysica acta 2014 Dec;1844(12):2222-8

Studies of the role of ubiquitination in the interaction of ubiquilin with the loop and carboxyl terminal regions of presenilin-2.

Ford DL, Monteiro MJ
Biochemistry 2007 Jul 31;46(30):8827-37

Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion.

Hiltunen M, Lu A, Thomas AV, Romano DM, Kim M, Jones PB, Xie Z, Kounnas MZ, Wagner SL, Berezovska O, Hyman BT, Tesco G, Bertram L, Tanzi RE
The Journal of biological chemistry 2006 Oct 27;281(43):32240-53

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescence analysis of Ubiquilin / Dsk2 was performed using 70% confluent log phase SH-SY5Y cells. The cells were fixed with 4% paraformaldehyde for 10 minutes, permeabilized with 0.1% Triton™ X-100 for 10 minutes, and blocked with 1% BSA for 1 hour at room temperature. The cells were labeled with Ubiquilin / Dsk2 (3D5E2) Mouse Monoclonal Antibody (Product # 37-7700) at 2µg/mL in 0.1% BSA and incubated for 3 hours at room temperature and then labeled with Goat anti-Mouse IgG (H+L) Superclonal™ Secondary Antibody, Alexa Fluor® 488 conjµgate (Product # A28175) at a dilution of 1:2000 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor® 555 Rhodamine Phalloidin (Product # R415, 1:300). Panel d represents the merged image showing nuclear localization. Panel e shows the no primary antibody control. The images were captured at 60X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of Ubiquilin / Dsk2 was done on SH-SY5Y cells. Cells were fixed with 70% ethanol for 10 minutes, permeabilized with 0.25% Triton™ X-100 for 20 minutes, and blocked with 5% BSA for 30 minutes at room temperature. Cells were labeled with Ubiquilin / Dsk2 Mouse Monoclonal Antibody (Product # 37-7700, red histogram) or with mouse isotype control (pink histogram) at 3-5 µg/million cells in 2.5% BSA. After incubation at room temperature for 2 hours, the cells were labeled with Alexa Fluor® 488 Rabbit Anti-Mouse Secondary Antibody (Product # A11059) at a dilution of 1:400 for 30 minutes at room temperature. The representative 10,000 cells were acquired and analyzed for each sample using an Attune® Acoustic Focusing Cytometer. The purple histogram represents unstained control cells and the green histogram represents no-primary-antibody control..

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 UBQLN1 overexpression reduces deposition of UBQLN2 inclusions compared to the brains of P497S mutant mice. a Staining of representative sagittal sections of the dentate gyrus (DG) (a-h), CA1 (i-p) and cortex (q-x) regions of the brain for UBQLN2 and DAPI in the four genotypes at 52 weeks of age. Scale bars shown. b Quantification of the number of UBQLN2 inclusions between 1 and 10 mum in size counted in identical size regions of the DG, CA1 and cortex regions (2 males and 1 female for each genotype). ** P < 0.01, *** P < 0.001, **** P < 0.0001. c Filter-trap assay showing detection of UBQLN2 inclusions in 50 mug of protein brain lysate analyzed for the four genotypes for animals at 52 weeks of age. Samples analyzed were: Non-Tg, 2 male (M) and 1 female (F); UBQLN1 all F; P497S, 1 M, 2 F; UBQLN1/P497S all M. d Quantification of the intensity of UBQLN2 immunoreactivity for the filter shown in c . ** P < 0.01

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Overexpression of UBQLN1 reduces UBQLN2 inclusions and ER stress in the spinal cord. a Immunofluorescence staining of the sections in the ventral horn region of the spinal cord for UBQLN2 and DAPI and of their combined staining. b Quantification of the number of UBQLN2 inclusions based on size in the spinal cord of the four genotypes at 52 weeks of age (2 males and 1 female for each genotype). * P < 0.05, ** P < 0.01. c Immunoblots of SC lysates for the different genotypes probed for the proteins shown. d Quantification of changes in phospho-eIF2alpha after normalizing for expression of total eIF2alpha protein (2 males and 1 female for each genotype). ** P < 0.01

37-7700

Antibody data